Biomimetic Polymer Nanomaterials Reprogram the Immunosuppressive Microenvironment in Hepatocellular Carcinoma
核心洞察
Biomimetic polymer-based nanomaterials combine synthetic polymers with cell membrane coatings to evade immune clearance and achieve targeted accumulation in the HCC tumor microenvironment.
These nanoplatforms can reprogram tumor-associated macrophages from M2 to M1 phenotype, enhance dendritic cell maturation, and restore CD8+ T cell cytotoxicity against liver cancer cells.
Preclinical studies demonstrate that cell membrane-camouflaged nanoparticles synergize with immune checkpoint inhibitors such as anti-PD-1 (搜索)/PD-L1 (搜索) to improve antitumor immunity and reduce systemic toxicity.
The immunosuppressive tumor microenvironment (TME) of hepatocellular carcinoma (搜索) (HCC) remains a formidable barrier to effective immunotherapy, with objective response rates to checkpoint inhibitors such as atezolizumab (27%) and nivolumab (20%) underscoring the urgent need for more effective strategies. A comprehensive review published in the International Journal of Nanomedicine now systematically examines how biomimetic polymer-based nanomaterials are being engineered to overcome hepatic immune tolerance and reprogram the immunosuppressive milieu that characterizes advanced liver cancer.
The liver's unique immunological landscape—shaped by continuous exposure to gut-derived antigens via the portal circulation—is maintained by Kupffer cells, liver sinusoidal endothelial cells, and resident antigen-presenting cells that enforce tolerance through IL-10 and TGF-β secretion, PD-L1 (搜索) expression, and the generation of regulatory T cells (Tregs). In HCC, this tolerogenic baseline is amplified: tumor-associated macrophages (TAMs) polarize to an M2-like phenotype, myeloid-derived suppressor cells (MDSCs) suppress effector T cells and NK cells via arginase-1 and reactive oxygen species, and aberrant checkpoint activation through PD-1 (搜索)/PD-L1 and CTLA-4 (搜索) drives T cell exhaustion.
Design Principles of Biomimetic Polymer Nanomaterials
Biomimetic polymer nanomaterials integrate synthetic polymers such as poly(lactic-co-glycolic acid) (PLGA (搜索)) and polyethylene glycol (PEG) with biologically inspired components—most notably cell membrane coatings derived from erythrocytes, immune cells, or tumor cells. These membrane-camouflaged nanoparticles exploit self-recognition markers: erythrocyte membranes naturally lack MHC molecules and express CD47 (搜索) to evade phagocytic clearance, while cancer cell membranes retain tumor antigens that enable homotypic targeting to HCC lesions.
Stimuli-responsive features are central to these designs. pH-responsive systems exploit the acidic extracellular pH of tumors (pH 6.5–6.8) to trigger conformational changes or cleavage of acid-labile bonds, ensuring site-specific release of immunotherapeutic cargo. Redox-sensitive materials leverage elevated glutathione and reactive oxygen species (ROS) concentrations in the TME to cleave disulfide bonds, while enzyme-responsive polymers incorporate peptide sequences cleaved by tumor-associated matrix metalloproteinases (MMPs). Dual and multi-stimuli responsive platforms combining pH and ROS triggers provide more precise control over immune activation and release kinetics.
Cell Membrane Camouflaging and Immune Modulation
Cell membrane camouflaged polymeric nanoparticles represent one of the most advanced classes of biomimetic nanomaterials. By coating PLGA (搜索) or PEGylated cores with membranes from tumor cells, macrophages, or erythrocytes, these systems achieve prolonged circulation times and enhanced tumor tropism. Preclinical evidence demonstrates that mesoporous silica nanoparticles cloaked with GPC3 (搜索)-targeted CAR-T cell membranes selectively homed to HCC cells and mediated tumor killing in murine models. Similarly, platelet membrane-camouflaged silica nanoparticles co-loaded with sorafenib and anti-PD-1 antibody (搜索) enhanced hepatic tumor targeting, activated cytotoxic T cells, and suppressed tumor growth.
Beyond membrane coating, biomimetic polymer micelles and vesicles—formed by self-assembly of amphiphilic block copolymers—enable co-encapsulation of hydrophobic and hydrophilic cargoes. Mannose-decorated polymersomes co-encapsulating ovalbumin antigen and a TLR7/8 (搜索) agonist significantly enhanced dendritic cell maturation and CD8+ T cell cytokine release. Cationic nano-octopus polymersomes loaded with antigen achieved efficient cytosolic delivery and STING (搜索) activation, resulting in antigen-specific CD8+ T cells and durable antitumor immunity.
Reprogramming the Immunosuppressive TME
At the mechanistic level, biomimetic polymeric nanomaterials interact with innate immunity by activating Toll-like receptor (TLR), NF-κB, and STAT signaling pathways in macrophages, driving M2-to-M1 repolarization and upregulation of pro-inflammatory gene expression. A pH-sensitive PLGA (搜索) nanoparticle delivering a STAT3 inhibitor (搜索) successfully reprogrammed TAMs from M2 to M1, enhanced CD8+ T cell responses, and significantly inhibited HCC growth in mice.
Nanomaterial-assisted cancer vaccines represent another promising application. Polymeric nanovaccines prepared from PLGA (搜索), polypeptides, and polysaccharides enable simultaneous delivery of tumor-associated antigens and immunoadjuvants, protecting antigens from degradation and promoting sustained release in lymphoid tissues. Cancer cell membrane-coated polymeric nanoparticles enhance uptake by antigen-presenting cells through homologous targeting and receptor-mediated endocytosis, resulting in improved MHC class I and II presentation and cross-priming of CD8+ cytotoxic T cells.
Synergy with Immune Checkpoint Inhibitors
Biomimetic nanomaterials have demonstrated notable synergy with immune checkpoint inhibitors in preclinical HCC models. By promoting immune cell infiltration and relieving T cell exhaustion, these platforms potentiate the efficacy of anti-PD-1 (搜索)/PD-L1 (搜索) and anti-CTLA-4 (搜索) antibodies. The combination of biomimetic surface modification with pH- or enzyme-sensitive release properties has yielded persistent tumor accumulation and activation of antitumor immune responses without significant systemic toxicity.
Challenges in Clinical Translation
Despite promising preclinical data, multiple hurdles impede clinical translation. The complexity of biomimetic fabrication—involving membrane extraction, polymer synthesis, surface functionalization, and controlled assembly—raises significant reproducibility concerns, with small variations in biological membrane composition producing large variations in biological properties. Scalability to GMP-compliant manufacturing remains problematic, as most laboratory techniques suffer from high batch-to-batch variability.
Long-term biosafety represents another critical concern. While many biomimetic nanocarriers appear biocompatible in short-term studies, comprehensive evaluations of chronic toxicity, immunogenicity, and off-target immune activation are lacking. The hybrid nature of these materials—combining synthetic polymers with biological molecules—poses regulatory challenges, as existing guidelines lack standardized protocols for evaluating nanobiological products.
The review authors emphasize that overcoming these barriers will require rigorous preclinical pharmacokinetic and biodistribution studies in HCC models, GLP toxicology assessments, and early-phase clinical trials. Standardized manufacturing protocols, quality control metrics for key attributes including residual solvents and endotoxin levels, and regulatory frameworks tailored to hybrid biomimetic materials are essential next steps toward realizing the clinical potential of these nanoplatforms for immune-responsive HCC therapy.